Cargando…

Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling

Gallbladder carcinoma is an aggressive malignancy with high mortality mainly due to the limited potential for curative resection and its resistance to chemotherapeutic agents. Here, we show that the histone deacetylase inhibitors (HDACIs) trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Peng, Guo, Zhiyong, Wu, Ying, Hu, Ronglin, Du, Jun, He, Xiaoshun, Jiao, Xingyuan, Zhu, Xiaofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542213/ https://www.ncbi.nlm.nih.gov/pubmed/26287365 http://dx.doi.org/10.1371/journal.pone.0136193

Ejemplares similares

BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
por: Liu, Shilei, et al.
Publicado: (2019)

Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway
por: Zhang, Wenwen, et al.
Publicado: (2020)

FOXK1 Promotes Proliferation and Metastasis of Gallbladder Cancer by Activating AKT/mTOR Signaling Pathway
por: Wencong, Ma, et al.
Publicado: (2020)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017)

Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
por: Meng, Wei, et al.
Publicado: (2019)

SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling
por: Qin, Yiyu, et al.
Publicado: (2017)

Short chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway
por: Park, Jeongho, et al.
Publicado: (2014)

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
por: Choi, Eun Jung, et al.
Publicado: (2014)

Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation
por: Rampazzo, Elena, et al.
Publicado: (2022)

Melatonin inhibits proliferation, migration, and invasion by inducing ROS-mediated apoptosis via suppression of the PI3K/Akt/mTOR signaling pathway in gallbladder cancer cells
por: Chen, Kunlun, et al.
Publicado: (2021)

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
por: Piao, Junjie, et al.
Publicado: (2016)

MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway
por: Shen, Liang, et al.
Publicado: (2015)

Ropivacaine inhibits wound healing by suppressing the proliferation and migration of keratinocytes via the PI3K/AKT/mTOR Pathway
por: Wu, Xiaoyang, et al.
Publicado: (2022)

HRK inhibits colorectal cancer cells proliferation by suppressing the PI3K/AKT/mTOR pathway
por: Wang, Haowei, et al.
Publicado: (2022)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
por: Chen, Liyan, et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Modulation of mTOR and epigenetic pathways as therapeutics in gallbladder cancer
por: Yang, Dong, et al.
Publicado: (2020)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway
por: Kapral, Małgorzata, et al.
Publicado: (2017)

Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway
por: Wang, Bin, et al.
Publicado: (2020)

Suppression of FAM83D Inhibits Glioma Proliferation, Invasion and Migration by Regulating the AKT/mTOR Signaling Pathway
por: Li, Xia, et al.
Publicado: (2022)

PKNOX2 suppresses lung cancer cell proliferation by inhibiting the PI3K/AKT/mTOR axis
por: Song, Minglei, et al.
Publicado: (2023)

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
por: Dong, Li Hua, et al.
Publicado: (2013)

Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer
por: Venkannagari, Sreedhar, et al.
Publicado: (2012)

AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines
por: Leal, Pamela, et al.
Publicado: (2013)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_btcrcbe1mrvt2eivs7bshrjkeb